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Epigenetic Landscape in Leukemia 
and Its Impact on Antileukemia 
Therapeutics
Bingzhi He, Julia Cathryn Hlavka-Zhang, Richard B. Lock  
and Duohui Jing
Abstract
Epigenomic landscape mapping in leukemia cells supports germ line muta-
tion studies to understand pathogenicity and treatment plans. The differential 
regulation of gene expression and heterogeneity between cell types during hema-
topoiesis and leukemia development is important in understanding oncogenesis. 
Oncogenesis in leukemia occurs at both genomic and epigenomic levels in order for 
hematological cells to evade lineage commitment. To ensure that therapies target 
the entire malignancy, it is important to consider the regulatory network that drives 
malignancy caused by mutations. Therapies tailored to respond to a patient-specific 
epigenetic landscape have the potential to minimize risk in administering chemo-
therapies that may not work. In this chapter, a focused study on childhood acute 
lymphoblastic leukemia (ALL) will be used as an example of the current research in 
the field of epigenetics in leukemia and the impact it carries on our understanding 
of the disease and treatment plans.
Keywords: epigenome, childhood acute lymphoblastic leukemia, chemotherapy, 
glucocorticoid, epigenetic drugs
1. Epigenetics overview
Epigenetics is a biological system that describes phenotypes and occurs due to 
differential regulation of genes (as opposed to genetic mutations). Current epi-
genetic studies include the control of basic biological functions [1], developmental 
biology [2, 3], the origin of disease [4], and cancer therapeutics [5]. Investigating 
the regulatory mechanisms driving these results involves genome-wide mapping of 
chromatin accessibility and conformation, transcription factor (TF) binding, DNA 
methylation, and histone modifications. Leukemia oncogenesis is a result of both 
genetic and epigenetic factors, whereby hematopoietic pathways are disrupted and 
leukemia cells are able to evade lineage commitment. This interdependence between 
altered genes and gene regulation is critical in cancer development. Consequently, a 
broader understanding inclusive of genomics and epigenomics will allow for devel-
opment of drug targets which may limit cancer progression, improve therapeutic 
response, and find novel targeted therapies.
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1.1 Regulation of gene expression
Multicellular eukaryotic organisms consist of a complex variety of different 
cells, all containing identical genomic DNA. The ability to create such diversity 
from identical duplicates of DNA is attributed to differential gene expression regu-
lation. Gene expression is as product of epigenetic regulatory systems. Differences 
within these regulations result in differential expressions and subsequently, cell 
types that differ in structure and function [6].
The three-dimensional organization of DNA is central to gene expression, as it 
depends on physical access to the gene to be expressed. Genomic DNA is condensed 
and wrapped around histone proteins, forming chromatin [7]. Condensed chromatin 
structures inhibit gene transcription by making the gene physically inaccessible for 
transcriptional machinery to access (Figure 1). To unfold chromatin structure and 
expose the gene for transcription, endogenous mechanisms and drugs modify the 
histone proteins around which the DNA is bound [8, 9]. Modifications which result in 
gene silencing include histone deacetylation and DNA methylation. To achieve differ-
ential expression profiles between cell types, cells have different gene access profiles 
controlled by protein mediation, external stimuli, and development of cells [10].
1.1.1 Histone deacetylation
Histone deacetylation involves the switching of histone proteins from a positive 
to neutral charge via the addition of an acetyl to a lysine residue within the histone 
tail. This change in charge will result in the DNA (negatively charged) separation 
from the histone due to repulsion forces of like charges. Separated DNA regions 
become accessible to transcriptional machinery as a result. When this mechanism 
is reversed and lysines are deacetylated, DNA is attracted back toward the protein, 
resulting in tight DNA wrapping, thus inaccessible for transcriptional machinery 
(Figure 2) [11]. The enzyme responsible for acetylation of histone proteins is called 
histone acetyltransferase (HAT), which opens the chromatin structure and allows 
transcription. Deacetylating enzymes which cause compacting of chromatin are 
called histone deacetylases (HDAC).
1.1.2 DNA methylation
DNA methylation is another mechanism of chromatin remodeling. CpG islands 
are target sites in the genome for methylation by the DNA methyltransferase 
Figure 1. 
Chromatin accessibility. Chromatin accessibility modulates gene expression. Densely packed chromatin (left) 
is inaccessible, preventing transcription factors (TFs), CCCTC-binding factor (CTCF), and polymerases from 
binding and subsequent gene expression. Opened chromatin structure (right) can be accessed by TFs, CTCF, and 
polymerases bindings, resulting in ability for gene transcription. Opened and closed chromatin structures are 
regulated by the acetylation status of histone proteins. Acetylated histones provide an open chromatin structure, 
while deacetylated histones form a closed chromatin structure. Adapted from Shlyueva et al., 2014 [10].
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(DNMT) enzyme. Of the CpG sites in gene promoter regions, 70% are primary 
targets for methylation. DNMT prevents gene transcription via physically prevent-
ing transcription factor binding and by methylating DNA. Methylated DNA binds 
to methyl-CpG-binding domain (MBD) proteins that in turn recruit proteins 
such as histone deacetylase and other chromatin-remodeling proteins. In this new 
environment, chromatin becomes compact and inactive, termed heterochromatin 
(repressed domain in Figure 2).
1.2 Epigenetics in leukemia
ALL population studies indicated a trend in disease peak around the age of 5, 
after which there is no increase in prevalence (Figure 3). Evidences suggest hema-
topoietic regulatory network probably most highly involved in leukemia develop-
ment at their highest in children <5 years old. Case-control studies have shown that 
the occurrence of childhood ALL is inversely linked to the degree of exposure to 
infections in the first few months of life [12, 13]. This suggests that there may be 
certain oncogenic factors present in the early days of a child’s life that lead to the 
development of ALL, rather than being present later on or in adulthood. Addressing 
these up- and downregulations of oncogenic factors in this critical stage of hema-
topoiesis will provide insight into pathogenesis and progression of ALL beyond the 
genetic level.
1.2.1 Oncogenesis driven by epigenetics (in ALL)
Epigenetics is still in the early stages of investigation and translational clini-
cal use. Primary testing in clinics focuses on cytogenic studies, categorizing 
disease based on genetic abnormalities and cell markers, and then treating the 
patient accordingly; screening gene expression to map out regulatory profiles of 
a tumor are less established. In acute lymphoblastic leukemia (ALL), subtypes 
are diagnosed based on cytogenic testing and testing for markers [14]. In vivo 
mouse studies, however, have indicated that in almost 75% of diagnosed cases, 
chromosomal changes alone are insufficient to induce ALL [15]. Investigation of 
Figure 2. 
Hierarchical layers of chromatin organization in mammalian cells. Adapted from Aranda et al., 2015 [11].
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genetic alterations alongside epigenetics microarrays of gene expression suggested 
an association between mutations and altered regulation in gene expressions 
during hematopoiesis in both B-ALL and T-ALL [14, 15]. Prenatal lesions and 
Figure 4. 
B-ALL development. Multiple mutations contribute to the development of ALL. Mutations in ALL 
predisposing genes, e.g., IKZF1, and initiating genes, e.G., ETV6-RUNX1, and MLL rearrangement will 
promote ALL development. Alterations in B-cell development genes, e.G., PAX5 and IKZF1, inhibit cell 
maturation, resulting in the accumulation of immature cells. This alone however is not enough to cause ALL 
pathogenesis. Cell cycle and lymphoid lineage regulatory gene expression must also be altered to promote its 
survival. Further alterations may induce chemoresistance. Adapted from Mullighan, 2013 [15].
Figure 3. 
Incidence of ALL per 100,000 populations in 2010. Source: Australian Institute of Health and Welfare 
(AIHW), 2014 [97].
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postnatal-acquired mutations have also shown impaired regulation and develop-
ment of progenitor B cells or T cells [16–18]. Together, these studies suggest that it 
is not mutations alone that act as oncogenic drivers but also an altered gene regula-
tory network.
Thus far, ALL oncogenic studies have reported prenatal genetic lesions and 
inherited genetic predisposition which neither can stand alone to account for the 
disease. Prenatal genetic lesions have been reported with an unknown patho-
genesis [18], and only 5% of ALL patients reported with an inherited genetic 
predisposition such as Down’s syndrome and Bloom’s syndrome [17, 19]. Figure 4 
indicates multiple genetic lesions contributing to an altered regulatory network 
in healthy lymphoid development toward a pathogenic ALL pathway [20–23]. 
Incomplete evidence regarding prenatal genetic lesions in ALL supports research 
into the epigenetic regulatory system in the development of ALL. Prenatal genetic 
lesions suggest the preleukemic states. Despite studies suggesting preleukemic 
state in utero, other studies show that the development of ALL in monozygotic 
twins follows a different time course. The difference in postnatal disease progres-
sion despite an identical prenatal state suggests the role of epigenetics in ALL 
manifestation [24–27].
2. Targeting epigenome of ALL in chemotherapy
Since drugs target distinct cell pathways relying on gene expression, access to 
target genes is crucial for the treatment to work. A common ALL chemotherapy 
regimen of glucocorticoids relies on activation of the glucocorticoid receptor (GR), 
which binds to glucocorticoid-response elements (GREs) in gene promoters, to 
induce expression of pro-apoptotic pathways [28]. Using a DNase hypersensitivity 
assay (DHA) to determine chromatin accessibility [29], the majority of GR binding 
to GREs were identified in open chromatin [8, 30]. Thus, glucocorticoid therapy 
is dependent on GRE accessibility which is defined by chromatin accessibility. 
Resistance and patient response to such drugs is thought to be dependent on their 
gene accessibility profiles.
2.1 Glucocorticoid-based chemotherapy: Focused study on ALL
2.1.1 Acute lymphoblastic leukemia (ALL)
ALL is a malignant disease in both adults and children, with mutations develop-
ing along the lymphoid lineage starting at the lymphoid progenitor cells. Normally, 
lymphoid cells have the potential to differentiate into B or T cells, which under 
oncogenic conditions give rise to either B-ALL or T-ALL [17, 21]. Hematopoietic 
stem cells (HSCs), in the bone marrow, are the origin of both lymphoid and 
myeloid lineages. The tight regulation of gene expression in HSCs determines the 
lineage pathway and development. During oncogenesis, molecular defects and 
abnormal genes regulation may alter the differentiation of HSC; these factors may 
also contribute to further alterations downstream in hematopoiesis [17, 31–36]. 
Alterations along the lymphoid lineage result in abnormal pre-lymphoid cells 
called lymphoblasts; these aggressively proliferate and gradually replace the nor-
mal hematopoietic cells in the bone marrow and blood. Accumulation of lympho-
blasts results in immunity retardation due to the insufficient amounts of mature 
lymphoid cells. Patients thus become immunocompromised and prone to various 
infectious diseases normally fought off by the immune system’s  lymphocytes 
[21, 37, 38].
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2.1.2 Glucocorticoids in the clinic
Glucocorticoids are naturally occurring steroid hormones that are widely 
recognized for their anti-inflammatory and immunosuppressing activities [39–41]. 
In leukemia, glucocorticoids are able to induce apoptosis in lymphoid cells. As such, 
glucocorticoid drugs such as dexamethasone and prednisolone are used as part of 
multi-agent chemotherapy regimens treating hematological malignancies [42–44], 
including ALL, chronic lymphocytic leukemia, multiple myeloma, and lymphoma. 
Due to pro-apoptotic pathway activation, glucocorticoids have remained the pivot 
point in chemotherapy treatment to combat ALL for 50 years [38, 45].
Glucocorticoids play a role in all three phases of treatment phases. During 
the remission-induction phase, glucocorticoids make up a significant portion of 
drug when administered in combination with vincristine and asparaginase and/or 
anthracycline. This initial high glucocorticoid portion aims to relieve at least 99% 
of the leukemic burden; the patient’s response is critical in determining the future 
course of treatment and determining chance of relapse and prognosis [46]. The 
following two chemotherapy phases are less intensive, involving re-administration 
of remission-induction drugs in addition to methotrexate and mercaptopurine [17]. 
To note, some patients do not need to be administered pulses of glucocorticoids in 
phases two and three of the therapy, due to patients’ contraindications [47]. This 
three-phase glucocorticoid regimen has seen an increase in ALL 5-year survival rate 
from 73–90% in the past 20 years [48], yet there still exits a subset of ALL patients 
who are resistant to glucocorticoids, resulting in poor prognosis.
2.1.3 Glucocorticoid mechanism of action
Glucocorticoid mode of action involves the activation of specific cellular 
pathways specific in lymphoid cells to induce cell death. Depending on cell type, 
cell-specific chromatin conformation provides the structural framework for 
transcription factor (TF) binding to regulate gene transcription that determines the 
ability of a cell to activate a pathway [49–51]. A cell-type-specific conformation is 
generated [11, 52] with each type having approximately 70,000–100,000 accessible 
chromatin domains and a network of cell-type-specific binding of transcriptional 
regulators [10, 53, 54]. Glucocorticoids are able to target intracellular pathways 
by interacting with the glucocorticoid receptor (GR) in the cytoplasm [55, 56]. 
The complex then translocates into the nucleus and binds at accessible chromatin 
domains containing glucocorticoid-response elements (GREs) at proximal pro-
moter regions and/or distal sites of a gene [57–59]. GR binding to GREs induces 
chromatin remodeling and activates gene transcription via recruitment of other 
transcription proteins [60, 61]. To keep gene transcription tightly regulated, GR 
binding is highly selective and predetermined by chromatin accessibility in differ-
ent cell types [8, 62]. Currently, the GR-binding landscape in different cell subsets, 
as well as between glucocorticoid-sensitive and resistant leukemia subsets, is yet to 
be established. Understanding this epigenetic landscape is crucial in understanding 
patient relapse or chemoresistance. Preliminary studies have started this investiga-
tion in pediatric ALL, to understand the mechanism of drug resistance in B-ALL.
2.1.4 Limitations to glucocorticoid treatment
While the glucocorticoid induces apoptosis pathway is still unclear, it is a 
 pro-apoptotic pathway exclusive to lymphoid cells despite widespread expressions 
of GR in most human tissues [63, 64]. Glucocorticoids are rarely efficacious in 
treating myeloid leukemia [65]. Due to this lymphoid-specific apoptosis pathway, 
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it is hypothesized that glucocorticoid-sensitive cells have a distinguished chromatin 
structure allowing for specific GR binding at GREs that glucocorticoid-resistant 
lymphoids, myeloid cells, and other tissue cells do not have [8, 66-69]. Therefore, 
understanding the lymphocyte-specific mechanisms of glucocorticoid-induced 
apoptosis, as well as the development of resistance to this class of steroid hormones, 
is critical in optimizing glucocorticoid-based therapies in the clinic.
The actions of glucocorticoids are cell type specific [65–67], although the exact 
molecular basis for this differential function remained elusive. While certain signal-
ing pathways resulting from ALL oncogenes appear to interfere with glucocorticoid 
actions resulting in resistance, epigenetic evidence suggests that in addition to 
genetic alterations, epigenetic factors contribute to resistance. For instance, inhibi-
tion of GR expression or its translocation to the nucleus in vitro and in vivo models 
via BTG1 or PTEN loss can cause glucocorticoid resistance by [70, 71]; however, GR 
function is rarely blocked in resistant ALL PDXs [72]. Mutations in epigenetic regu-
lators such as KMT2D, CREBBP, and HDAC7, in two of five resistant PDX models, 
could not account for abnormal epigenetic changes. Mutations in various signaling 
pathways [73–76] have been reported to impair glucocorticoid-induced apoptosis 
in ALL by downregulating the GR-activated pro-apoptotic gene, BIM expression. 
The importance to study beyond gene mutations, toward epigenetic mapping of GR 
binding, will provide a deeper understanding into individual drug response.
2.2 Epigenetic landscape shapes the response to glucocorticoids in leukemia
Lymphocyte-specific enhancers associated with glucocorticoid-induced apop-
tosis were identified in cell-wide studies [5, 28]. Moreover, aberrations at these 
enhancers were observed in glucocorticoid-resistant ALL cells. Similarly, nonlym-
phoid cells also exhibited inaccessible chromatin at these enhancers, providing 
insights into the cell-type-specific actions of glucocorticoids. A link between 
epigenetic differences and cell-type-specific actions of glucocorticoids are essential 
in the treatment determining treatment approaches for lymphoid malignancies. 
Lymphocyte-specific epigenetic modifications pre-determine glucocorticoid 
resistance in ALL and may account for the lack of glucocorticoid sensitivity in 
other cell types. Recent findings suggest that in glucocorticoid-sensitive cells, GR 
cooperates with the structural protein, CTCF, at lymphocyte-specific regulatory 
domains to mediate the formation of a transcriptionally active DNA loop to trig-
ger gene transcription, which can be inhibited by increased DNA methylation in 
glucocorticoid-resistant ALL. By using a comprehensive map of chromatin acces-
sibility, CTCF binding, histone modifications, and DNA methylation in normal and 
malignant cell types, there is evidence of regulatory heterogeneity in the epigenome 
of different cell types. Azacytidine, a DNA demethylating drug that is routinely 
used in the clinic, could partially reverse these changes and restore glucocorticoid-
induced gene expression and glucocorticoid sensitivity. This indicates that reversal 
of epigenetic changes may lead to improvements in the use of glucocorticoids for 
the management of lymphoid malignancies.
3. Epigenetic drugs
3.1 What are epigenetic drugs?
Epigenetic drugs inhibit and manipulate different epigenetic regulators 
involved in histone remodeling. Drugs which target epigenetic regulators can open 
closed chromatin structures commonly found in chemotherapy-resistant patients. 
Germ Line Mutations Associated Leukemia
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Epigenetic regulators can be divided into different categories based on their method 
of modification: epigenetic writers, readers, and erasers (Figure 5).
Epigenetic regulators determine gene expression, and an understanding of 
them allows for the development of drugs to regulate gene expression over epigen-
etic marks. Epigenetic writers lay down epigenetic marks on DNA or amino acid 
residues on histones tails [77]. Examples include histone acetyltransferases (HATs), 
histone methyltransferases (HMTs), and protein arginine methyltransferases 
(PRMTs). Drugs which target these are DNA hypomethylating agents, bromodo-
mains, and HDAC inhibitors. Epigenetic readers are proteins that contain bromo-
domains, chromodomains, and Tudor domains allowing them to bind to specific 
epigenetic marks on chromatin. Epigenetic erasers such as histone deacetylases, 
lysine demethylases, and phosphatases catalyze the removal of epigenetic marks.
3.2 Categories of epigenetic modifying drugs
The epigenetic drugs to be discussed are designed to target different epigenetic 
regulators responsible for gene silencing.
Figure 5. 
Epigenetic reader, writer, and eraser. Epigenetic writers such as histone acetyltransferases (HATs), histone 
methyltransferases (HMTs), protein arginine methyltransferases (PRMTs), and kinases lay down epigenetic 
marks on amino acid residues on histone tails. Epigenetic readers are proteins that contain bromodomains, 
chromodomains, and Tudor domains, allowing them to bind to these epigenetic marks. Epigenetic erasers 
such as histone deacetylases, lysine demethylases, and phosphatases catalyze the removal of epigenetic marks. 
Together they modulate chromatin structures and regulate various DNA-dependent biological processes such as 
DNA synthesis and replication. Adapted from Falkenberg and Johnstone, 2014 [77].
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3.2.1 DNMT inhibitors
During preparation of genetic information in the S phase of the cell cycle, 
replication machinery is responsible for DNA replication, and DNMT functions 
duplicate methylation status by adding methyl groups to the DNA accordingly 
(Figure 6). DNMT inhibitors, azacytidine and decitabine, prevent DNMT 
methylation. Azacytidine and decitabine are metabolized inside cells into 5-aza-
2′-deoxycytidine-triphosphate. The difference between DNMT bounding to 
5-aza-2′-deoxycytidine-triphosphate and DNMT bound to cytosine is used to 
inhibit DNMT. As illustrated in Figure 7, DNMT reversibly binds with cytosine, 
which allows DNMT to be released from DNA through beta-elimination once 
methylation is completed. DNMT binding to 5-aza-2′-deoxycytidine-triphosphate 
establishes a covalent bond preventing beta-elimination; therefore, DNMT 
remains bond to the DNA. Subsequently, the error triggers DNA damage signal-
ing and the trapped DNMT is degraded. As a result, methylation markers get lost 
during DNA replication [78]. Demethylated DNA allows for an open chromatin 
structure to be accessed by transcription factors induce by chemotherapeutic 
drugs such as glucocorticoids.
Single-agent study conducted by Khaldoun Al-Romaih’s group showed that 
decitabine therapy had a cytotoxic effect mediated by the removal of hypomethyl-
ation of the CpG position both in vivo and in vitro. The cells treated with decitabine 
showed significant cell death in vitro, and six pro-apoptotic genes (GADD45A, 
HSPA9B, PAWR, PDCD5, NFKBIA, and TNFAIP3) were induced to ≥ twofold 
in vivo [79]. Combination therapy trials revealed the value of DNMT inhibition 
in addition to current therapeutic regimens. In one clinical trial in refractory ALL 
patients, decitabine combined with hyper-CVAD (fractionated cyclophosphamide, 
vincristine, doxorubicin, and dexamethasone alternating with high-dose metho-
trexate and cytarabine) was able to achieve complete remission in patients that did 
Figure 6. 
Effect of epigenetic modification on gene expression. Activation of gene transcription needs transcription 
factor binding to the promoter region of the gene. Without DNA methylation, transcription factors and RNA 
polymerase II (RNA pol II) can bind to DNA segments; however, when methyl group is added to the DNA by 
DNA methyltransferase (DNMT), the methylation not only impedes the binding of transcription factors to 
DNA but also recruits histone deacetylase (HDAC) causing chromatin structure to become compacted, which 
places spatial limitation for transcription factor binding [83].
Germ Line Mutations Associated Leukemia
10
not respond to hyper-CVAD treatment alone. Patient DNA analysis confirmed that 
the hypomethylation status in the combination treatment group was the reason 
for reversal of resistance [80]. A number of other clinical studies provided similar 
results, showing synergistic effects between hypomethylating agents and several 
chemotherapy agents. Agents such as prednisolone, etoposides, doxorubicin, and 
cytarabine were shown to increase chemosensitivity in leukemia cells [81–84]. 
Although promising not all experimental groups responded, indicating the need for 
further research into the complex network of interactions.
3.2.2 HDAC inhibitors
An open chromatin structure also relies on the relatively loose interactions 
between DNA and histone proteins. The addition of an acetyl groups to the lysine 
amino acids on histone proteins by histone acetyltransferases (HATs) reduces 
the positive charges on the histone proteins. DNA, negatively charged, is there-
fore less attracted to these now less positive histones, thus less tightly bound 
and easier for transcription factors to access [83]. Conversely, the removal of 
acetylation by histone deacetylase (HDAC) forms condensed heterochromatin 
and silences critical apoptosis gene transcriptions. HDAC inhibitors prevent this 
form of gene silencing and are used alongside standard chemotherapy to promote 
pro-apoptotic pathways.
HDAC enzyme family consists of Class I (HDAC1, HDAC2, HDAC3, HDAC8), 
Class II (HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, HDAC10), Class III (SIRT1, 
SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7), and Class IV (HDAC11). HDAC 
inhibitors are designed as either selective inhibitors or pan-inhibitors (against all 
types of HDAC). Evidence that some HDACs play a stronger role in cancer devel-
opment and patient prognosis than others makes specific HDAC inhibitors more 
appealing for clinical use. A study of 94 pediatric ALL patients showed differential 
HDAC expressions between the T-ALL and B-ALL subtypes. For T-ALL, HDAC1 
and HDAC4 showed a higher expression than in B-ALL. T-ALL patients with 
HDAC3 expression above the cohort median also displayed a significantly higher 
5-year event-free survival (EFS). In B-ALL, HDAC5 had higher expression than 
Figure 7. 
Reversible binding of cytosine with DNMT in DNA methylation process versus irreversible binding of 
5-azacytosine with DNMT when leukemia cells were treated with azacytidine, which leads to degradation of 
DNMT and subsequent loss of methylation. Adapted from Stresemann and Lyko, 2008 [78].
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in T-ALL. In both T-cell and B-cell ALL, HDAC7 and HADC9 expression levels 
higher than the cohort median were associated with a lower 5-year EFS [85]. These 
trends suggest that Class II HDACs are associated with poorer prognosis; hence, a 
specific inhibition of this class of HDACs is important.
3.2.3 Bromodomain inhibitors
Bromodomains (BRDs) are epigenetic readers which selectively bind to acetylate 
lysine of histones tails, regulating gene expression [86]. Bromodomain-containing 
proteins that target genes are primarily cell cycle M/G1 genes in mitotic chromatin 
(expressed at the end or immediately after mitosis); late-phase genes were not 
found to be BRD4 bound. M/G1 gene expression during telophase coincides with 
histone H3 and H4 acetylation in those genes. BRD binding to M/G1 genes was 
associated with recruitment of positive transcription elongation factor b (P-TEFb), 
resulting in translational memory in the daughter cells [87]. BRD binds to MYC and 
activates enhancer-binding protein 4 (AP4) promoters. AP4 is a key mediator of 
mitogenicity for proto-oncogene MYC [88]. Upon AP4 activation by MYC, repress-
ing cell cycle arrests gene P21 [88].
JQ1 is a BRD inhibitor which acts on the MYC-AP4 axis [89]. Direct inhibition 
by JQ1 of BRD binding to the MYC and AP4 promoters indirectly results in cell 
cycle arrest as a P21-induced response to DNA damage P53 or TGFb/Smad signaling 
pathways [90].
3.3 Epigenetic drugs in chemotherapy
Epigenetic drugs are useful in combination with cytotoxic drugs, due to their 
ability to allow for access to pro-apoptotic pathways, otherwise blocked by epigen-
etic silencing. In a subset of leukemia patients, resistance to cytotoxic drugs such 
as glucocorticoids and methotrexate is a result of inaction of pro-apoptotic genes. 
Theoretically, applying epigenetic drugs such as those mentioned above should 
remove the epigenetic modification such that pro-apoptotic genes may go from 
repression to promotion.
3.3.1 Epigenetic drugs to treat glucocorticoid resistance
Chromatin conformation and gene expression studies at the glucocorticoid-
induced pro-apoptotic BIM gene in drug-sensitive versus resisted lymphoid cells 
indicated that glucocorticoid resistance in ALL patients may be due to epigenetic 
modifications.
3.3.2 DNMT inhibitors
Studies showed closed DNMT catalyzed chromatin structure caused by DNA 
methylation impedes the transcription of BIM; lymphocyte-specific open chro-
matin structure determines BIM expression. Therefore, modifying chromatin 
structure would allow for BIM expression. Common cytosine analog hypometh-
ylating drugs, decitabine or azacytidine, used in ALL act by inhibiting DNMT 
activity thus reactivate silenced genes. Once metabolized inside cells into 5-aza-2′-
deoxycytidine-triphosphate, cytosine substrates on DNA replication machinery 
are replaced by the drug analog. These DNMT inhibitors have been proven to work 
synergistically with glucocorticoids in glucocorticoid-resistant ALLs, increasing the 
overall effectiveness of the therapeutic regimens [84].
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3.3.3 HDAC inhibitors
Suberoylanilide hydroxamic acid (SAHA; Vorinostat) is an HDAC inhibitor 
shown to work synergistically with different chemotherapies. Glucocorticoid-
resistant ALL cases were associated to a correlation between histone H3K9 deacety-
lation and pro-apoptotic gene, BIM, repression [91, 92]. SAHA acts to increase 
acetylation at H3K9 for BIM expression. Another chemocytotoxic pathway involves 
FPGS conversion of methotrexate to a cytotoxic product responsible for apoptosis, 
MTX-PGs. HDAC1 represses FPGS via epigenetically silencing. The combination 
of SAHA with methotrexate was shown to increase FPGS expression by two- to 
fivefolds, thus increasing cytotoxic activity [93].
3.4 Combination therapy
Combination therapy aims to bring synergistic effects by targeting both cell 
death pathway (chemotherapy, e.g., glucocorticoids) and access to this pathway 
(epigenetic drug). Of the clinical trials underway, the use of relatively high doses 
of 5-azacitidine (150 mg/m2 as a continuous infusion daily × 5 days) is combined 
with cytarabine in patients relapsed from cytarabine alone. It was hypothesized 
that treatment with 5-azacitidine could induce expression of deoxycytidine kinase. 
Two out of the 17 patients achieved complete responses (CR). In another study, 
decitabine was combined with either amsacrine or idarubicin in patients with acute 
leukemia. CR was achieved in 36% (23 out 63) of patients, with a median disease-
free survival of 8 months [82].
Using a hypomethylating agent such as decitabine, glucocorticoids in resistant 
ALL patients had the potential to expose the pro-apoptotic gene BIM, making 
it available for GR binding and subsequent transcription; thus reversing patient 
glucocorticoid resistance [5]. This should especially increase the rate of CR among 
the patients with glucocorticoid-resistant ALL and prolong event-free survival as 
suggested in preclinical trial model.
4. Conclusion
Knowledge of gene regulation has deepened the understanding of cellular mech-
anisms and disease development. In leukemia, genomic and epigenomic landscapes 
together provide crucial disease mechanism of pathogenicity and drug resistance 
[94–96]. Epigenetics is the driver of life and diversity of different organisms, and 
equally able to dysregulate cells and cause diseases such as leukemia. Hematopoiesis 
is a tightly controlled process essential for life, therefore, unless appropriately 
regulated, susceptible to regulatory errors as oncogenic drivers alongside mutations. 
Lineage-specific landscapes have been shown to be involved in hematopoiesis and 
leukemia evolution [51], providing a backbone for understanding targetable and 
non-targetable sites within different leukemic subtypes.
Studying a level of cell dysfunction preceding DNA mutations has allowed for 
understanding into pathogenesis and drug resistance which could not be correlated 
to DNA sequencing. Understanding resistance to chemotherapies, lowering patient 
prognosis, has been enlightened in epigenetic studies. For example, actions of glu-
cocorticoids are cell type-specific and can be used in lymphocyte-specific leukemia 
cells to induce cell death [66, 67]. Analysis between genome-wide lymphocyte-
specific open chromatin domains (LSOs) and integrated LSOs with glucocorticoid-
induced RNA transcription and chromatin modulation in ALL was performed 
to causes glucocorticoid resistance beyond gene mutations [5]. LSOs critical for 
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glucocorticoid-induced apoptosis were identified as well as structural protein CTCF 
binding in this region. These findings showed that upon GR binding to the LSO 
and CTCF binding, DNA would loop at the pro-apoptotic BIM gene and could be 
expressed. Crucially, DNA methylation (closed chromatin structure) was present in 
glucocorticoid-resistant ALL and nonlymphoid cell types, preventing DNA looping 
and BIM expression.
Understanding the importance of chromatin accessibility has allowed for identi-
fication of glucocorticoid sensitivity in cells and provides promising drug response 
predictions. Furthermore, development of epigenetic drugs that may modify 
chromatin to be accessible is currently being investigated. This would allow for 
more effective drug treatments to disrupt the oncogenesis driven via dysregulated 
pathways.
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